Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Report reveals year of research success

publication date: Feb 2, 2012
 | 
author/source: The Institute of Cancer Research
The Institute of Cancer Research (ICR)The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust have today launched their Joint Annual Research Report for 2010/11, highlighting a year of significant achievements.

The ICR and The Royal Marsden have been working together for over 100 years to improve the lives of patients diagnosed with cancer and today form Europe's largest comprehensive cancer centre. By working as one integrated centre, the two organisations are able to translate basic science quickly and effectively into clinical benefit for patients and to use observations from clinical trials to drive further basic research.

 "Our unique partnership means that we can deliver and implement innovations in cancer treatment in a way few other organisations can match," says the ICR's Chief Executive Professor Alan Ashworth. "Working together, we are making a global impact on cancer research and treatment and changing the lives of people with cancer."

"This year has been one of significant achievement and progress," says The Royal Marsden's Chief Executive, Cally Palmer. "We were delighted to retain our status as the only specialist biomedical research centre for cancer in England.

"During the last year we began building our centre for molecular pathology, which will bring scientists and clinicians together to allow us to develop new strategies and discoveries in molecular diagnostics. We've also made very significant progress in our world leading drug development unit, making a huge impact on the drugs available to patients worldwide."

The report, which this year has moved online, features short films on the joint research strategy, the new centre for molecular pathology and the huge success of abiraterone acetate receiving a license in Europe and the US for the treatment of advanced prostate cancer, the culmination of 20 years' of hard work by the organisations' scientist and clinicians.

Other highlights include patient trials of the drug vemurafenib, the identification of new inheritable genes that predispose men to prostate cancer, advances in radiotherapy that have helped to improve patient outcome, and our latest cancer drug discovery and development activity.

The joint annual research report is available at www.jointcancerreport.org


 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events